Emergent BioSolutions Inc. announced the appointment of Dr. Simon Lowry as its new Chief Medical Officer and Head of Research and Development. This executive leadership change is part of Emergent's ongoing transformation efforts.
Dr. Lowry's role will be critical in guiding the company's scientific and clinical strategies, particularly in developing solutions for public health threats. His appointment is expected to contribute to the company's long-term product pipeline and innovation goals.
In addition to Dr. Lowry's appointment, Jessica Perl has been promoted to General Counsel and Corporate Secretary. These appointments aim to strengthen Emergent's executive management team as it continues to evolve its business model.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.